Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

CEO Bob Bradway said Amgen is "well advanced" in preparing to launch a Phase 3 testing round of MariTide in order to have ...

In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more than 7% on Tuesday after a ...

Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...

A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off Amgen’s market cap. The tab contains ...